Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 7/20 | 0.57 |
| ▸ | CA2 | P00918 | 7/20 | 0.57 |
| ▸ | CA12 | O43570 | 6/20 | 0.57 |
| ▸ | CA9 | Q16790 | 6/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12772839 | 0.98 | TDP1 (0.73) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL14571199 | 0.98 | TDP1 (0.73) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL21996829 | 0.98 | TDP1 (0.73) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1588079 | 0.98 | TDP1 (0.73) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL694362 | 0.96 | TDP1 (0.65) | TDP1MEN1GAAKMT2AMAOA | |
| Hydrochloric Acid SCHEMBL30183864 | 0.94 | TDP1 (0.62) | TDP1MEN1GAAKMT2AMAOA | |
| Bromide SCHEMBL17818451 | 0.94 | TDP1 (0.62) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3020258 | 0.92 | TDP1 (0.81) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3025184 | 0.90 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL136815 | 0.90 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924117-A | Preparation method of 4- (methylamino) butyl carbamic acid tert-butyl ester | 苏州昊帆生物股份有限公司 | 2024-04-26 | — | — | CN | claimed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4608808-A1 | SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOF | Basecamp Bio Inc. (KY) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025151487-A2 | SMALL-MOLECULE INHIBITORS OF ADAR1 | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-07-17 | — | — | WO | disclosed |
| US-12318452-B2 | Degraders of WEE1 kinase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-7655808-B2 | Leptomycin compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2010003658-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2010-01-14 | — | — | WO | disclosed |
| US-7566734-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20090137647-A1 | Modified Macrophage Migration Inhibitory Factor Inhibitors | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2009-05-28 | — | — | US | disclosed |
| US-20090137647-A1 | Modified Macrophage Migration Inhibitory Factor Inhibitors | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2009-05-28 | — | — | US | disclosed |
| US-20090042837-A1 | LEPTOMYCIN COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| US-7446196-B2 | Leptomycin compounds | KOSAN BIOSCIENCES, INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| WO-2007112036-A2 | MODIFIED MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, GLP1R | TDP1 3907/4885MEN1 4809/4885GAA 3027/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885GAA 1234/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885GAA 1234/4885 |
| US-20090137647-A1 | Modified Macrophage Migration Inhibitory Factor Inhibitors | MIF, MSR1, MMP12 | TDP1 4742/4885MEN1 754/4885GAA 2549/4885 |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, FFAR3 | TDP1 2943/4885MEN1 4763/4885GAA 3705/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TDP1 2415/4885MEN1 606/4885GAA 172/4885 |
| US-12318452-B2 | Degraders of WEE1 kinase | WEE1, WEE2, PPME1 | TDP1 632/4885MEN1 1700/4885GAA 455/4885 |
| US-20090042837-A1 | LEPTOMYCIN COMPOUNDS | TPD52L2, MRPL12, LMNB1 | TDP1 3890/4885MEN1 61/4885GAA 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.